Incyte Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 6,957,970,000.00 | ROE | 74.27 % |
| Balance Sheet | Total Equity | 5,167,478,000.00 | ROA | 18.49 % |
| Cashflow | Capital Expenditures | -83,867,000.00 | P/FCF | 16.53 |
| Cashflow | Free Cash Flow | 1,354,632,960.00 | – | – |
| Cashflow | Operating Cash Flow | 1,413,498,000.00 | P/CF | 15.84 |
| Income | Earnings per Share (diluted) | 6.41 | Div. Yield | – |
| Income | Net Income | 1,286,650,000.00 | P/E | 17.41 |
| Income | Shares Outstanding | 198,460,009.00 | P/B | 4.33 |
| Income | Total Revenue | 5,141,240,000.00 | P/S | 4.36 |
Ratios calculated on: 10/14/2026
Company Description
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.incyte.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more